JP2004536045A - 基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法 - Google Patents

基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法 Download PDF

Info

Publication number
JP2004536045A
JP2004536045A JP2002576969A JP2002576969A JP2004536045A JP 2004536045 A JP2004536045 A JP 2004536045A JP 2002576969 A JP2002576969 A JP 2002576969A JP 2002576969 A JP2002576969 A JP 2002576969A JP 2004536045 A JP2004536045 A JP 2004536045A
Authority
JP
Japan
Prior art keywords
cyclopamine
treatment
cells
bcc
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002576969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536045A5 (OSRAM
Inventor
タシ、シナン
アヴチ、オクタイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2004536045(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2004536045A publication Critical patent/JP2004536045A/ja
Publication of JP2004536045A5 publication Critical patent/JP2004536045A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2002576969A 2001-07-02 2001-07-02 基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法 Pending JP2004536045A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009074496A Division JP2009143963A (ja) 2009-03-25 2009-03-25 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物

Publications (2)

Publication Number Publication Date
JP2004536045A true JP2004536045A (ja) 2004-12-02
JP2004536045A5 JP2004536045A5 (OSRAM) 2005-10-06

Family

ID=21619326

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002576969A Pending JP2004536045A (ja) 2001-07-02 2001-07-02 基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法
JP2010028010A Expired - Fee Related JP5424923B2 (ja) 2001-07-02 2010-02-10 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
JP2013193304A Ceased JP2014028834A (ja) 2001-07-02 2013-09-18 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010028010A Expired - Fee Related JP5424923B2 (ja) 2001-07-02 2010-02-10 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
JP2013193304A Ceased JP2014028834A (ja) 2001-07-02 2013-09-18 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用

Country Status (14)

Country Link
EP (4) EP2862570A1 (OSRAM)
JP (3) JP2004536045A (OSRAM)
KR (1) KR20090125833A (OSRAM)
CN (2) CN1525859B (OSRAM)
AT (2) ATE305300T1 (OSRAM)
AU (1) AU2001272892B8 (OSRAM)
BR (1) BR0117063A (OSRAM)
CA (1) CA2452151C (OSRAM)
DE (2) DE60113733T2 (OSRAM)
DK (2) DK1401438T3 (OSRAM)
ES (3) ES2534400T3 (OSRAM)
PT (1) PT1411938E (OSRAM)
RU (1) RU2312661C2 (OSRAM)
WO (2) WO2002078703A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
EP2862570A1 (en) * 2001-07-02 2015-04-22 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
EP2511298B1 (en) 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Compositions and Methods for Treating Cancer based on human FZD receptors
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2008070357A2 (en) * 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008109184A1 (en) * 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
JP2010520310A (ja) * 2007-03-07 2010-06-10 インフィニティ・ディスカバリー・インコーポレイテッド シクロパミンラクタム類似体及びその使用方法
CN104059124A (zh) 2007-12-27 2014-09-24 无限药品股份有限公司 立体选择性还原的方法
CN101990542A (zh) * 2008-02-08 2011-03-23 德克萨斯大学董事会 环巴胺酒石酸盐及其用途
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011123785A2 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2015096654A1 (zh) * 2013-12-26 2015-07-02 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
HRP20251395T1 (hr) 2015-06-04 2026-02-13 Sol-Gel Technologies Ltd. Topikalne formulacije za isporuku spojeva inhibitora hedgehog signalnog puta i njihova uporaba
US20170231968A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
CN117940170A (zh) 2021-09-13 2024-04-26 辛南·塔斯 有效干预人类衰老和衰老疾病及其效果
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052534A1 (en) * 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
WO2000041545A2 (en) * 1999-01-13 2000-07-20 Ontogeny, Inc. Regulators of the pct or smoothened pathway, compositions and uses related thereto
WO2001027135A2 (en) * 1999-10-13 2001-04-19 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
RU2232758C2 (ru) * 1998-09-23 2004-07-20 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием
ES2233383T3 (es) * 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
AU1935801A (en) * 1999-11-30 2001-06-12 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
EP2862570A1 (en) * 2001-07-02 2015-04-22 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052534A1 (en) * 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
WO2000041545A2 (en) * 1999-01-13 2000-07-20 Ontogeny, Inc. Regulators of the pct or smoothened pathway, compositions and uses related thereto
WO2001027135A2 (en) * 1999-10-13 2001-04-19 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物

Also Published As

Publication number Publication date
CA2452151C (en) 2012-01-03
EP1401438B1 (en) 2005-09-28
EP1401438A1 (en) 2004-03-31
PT1411938E (pt) 2005-11-30
DE60204966T2 (de) 2006-05-18
WO2002078703A1 (en) 2002-10-10
CN1525859B (zh) 2010-05-05
JP2014028834A (ja) 2014-02-13
DK1411938T3 (da) 2005-11-07
DE60113733T2 (de) 2006-06-29
WO2002078703A8 (en) 2003-06-12
DK1401438T3 (da) 2006-02-13
EP2216022A1 (en) 2010-08-11
ES2250434T3 (es) 2006-04-16
EP2862570A1 (en) 2015-04-22
AU2001272892B8 (en) 2006-05-04
ATE299022T1 (de) 2005-07-15
WO2002078704A1 (en) 2002-10-10
DE60204966D1 (de) 2005-08-11
EP1561464A2 (en) 2005-08-10
RU2312661C2 (ru) 2007-12-20
CN1230169C (zh) 2005-12-07
EP2216022B1 (en) 2015-01-07
CN1522146A (zh) 2004-08-18
EP1561464A3 (en) 2007-04-25
DE60113733D1 (de) 2006-02-09
BR0117063A (pt) 2004-07-27
ES2534400T3 (es) 2015-04-22
ATE305300T1 (de) 2005-10-15
CA2452151A1 (en) 2002-10-10
RU2004103074A (ru) 2005-05-10
KR20090125833A (ko) 2009-12-07
ES2246011T3 (es) 2006-02-01
JP2010132691A (ja) 2010-06-17
JP5424923B2 (ja) 2014-02-26
AU2001272892B2 (en) 2006-03-16
CN1525859A (zh) 2004-09-01

Similar Documents

Publication Publication Date Title
CA2452151C (en) Use of cyclopamine, an inducer of the differentiation and apoptosis of the basal cell carcinoma (bcc) cells, in the treatment of bcc's and other tumors that use the hedgehog/smoothened pathway for proliferation of apoptosis
US7893078B2 (en) Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
AU2001272892A1 (en) Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
US20140242012A1 (en) Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
Gorai et al. Update of pathophysiology and treatment options of seborrheic keratosis
JP5744770B2 (ja) ナス属（ｓｏｌａｎｕｍ ｇｅｎｕｓ）植物からの水溶性抽出物での炎症及び皮膚の光損傷の治療及び／又は予防、並びに皮膚の光防護
JPH11503111A (ja) ヒドロキシル化芳香族のタンパク質架橋性化合物の局所塗布による、上皮過増殖症の治療法
JP2009143963A (ja) 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
CN114432295A (zh) 野黄芩素在制备预防或治疗瘢痕的药物中的用途
RU2308948C2 (ru) Применение циклопамина для лечения базально-клеточной эпителиомы (карциномы) и других опухолей
JP2014028835A (ja) 基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法
CN121015680B (zh) 野黄芩苷与红景天苷联合在治疗日光性皮炎中的应用
US20120258937A1 (en) Targeting Estrogen Receptors in the Treatment of Lymphangioleiomyomatosis
Das et al. Malignant diseases of the skin
CN118176002A (zh) 局部使用akt抑制剂来预防、治疗和改善皮肤疾病、病况和病症的组合物和制剂
CN101904852A (zh) 环杷明在治疗基底细胞癌及其它肿瘤中的应用
SK16042002A3 (sk) Farmaceutický prípravok na topickú aplikáciu
BR102015024093A2 (pt) composição farmacêutica compreendendo [10]-gingerol e uso como molécula antitumoral e antimetastática

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20071019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080617

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090325

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090610

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20091120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110601

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110609

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120120